Daily news about corporate social responsibility, ethics and sustainability
Tags (14) : drug development
Lakewood-Amedex Appoints Joseph Tucker to Board After Nasdaq Listing
04/28/2026 | Companies
antibiotic resistance,
antimicrobial drugs,
biotech leadership,
biotechnology,
Bisphosphocin,
board of directors,
capital markets,
clinical trials,
clinical-stage biotech,
corporate governance,
diabetic foot ulcers,
drug development,
Enveric Biosciences,
healthcare innovation,
Joseph Tucker,
Lakewood-Amedex Biotherapeutics,
Nasdaq listing,
neurological disorders,
neuropsychiatric disorders,
Nu-3,
pipeline development,
small-molecule therapeutics,
strategic growth
Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Abu Dhabi,
Alzheimer’s disease,
Arcera Life Sciences,
biologics,
biotechnology,
biotechnology incubation,
cardiometabolic diseases,
cell therapy,
China,
drug development,
emerging markets,
Fosun Pharma,
gene therapy,
global healthcare,
healthcare infrastructure,
innovation,
international collaboration,
joint ventures,
licensing,
life sciences,
market access,
memorandum of understanding,
Middle East healthcare,
MoU,
neurodegenerative diseases,
neuroscience,
oncology,
pharmaceutical industry,
R&D,
radiopharmaceuticals,
rare diseases,
research and development,
siRNA therapies,
small molecules,
strategic partnership,
UAE,
Vision 2030
Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
6MW5311,
acute myeloid leukemia,
AML,
biopharmaceuticals,
biotechnology,
bispecific antibody,
cancer research,
CD3,
chronic myelomonocytic leukemia,
clinical trials,
CMML,
cytotoxicity,
drug development,
FDA,
hematologic malignancies,
immune synapse,
immunotherapy,
IND application,
LILRB4,
Mabwell,
MM,
multiple myeloma,
NMPA,
oncology,
preclinical studies,
stem cell transplantation,
steric hindrance,
T cell engager,
targeted therapy,
TCE technology,
tumor inhibition
Jazz Pharmaceuticals Showcases Epilepsy and Narcolepsy Research at AAN 2026
04/09/2026 | Companies
AAN 2026,
American Academy of Neurology,
behavioral symptoms,
cannabidiol,
clinical research,
cognitive function,
Dravet syndrome,
drug development,
DUET study,
EpiCom study,
Epidiolex,
epilepsy,
Jazz Pharmaceuticals,
Lennox-Gastaut syndrome,
medical conference,
narcolepsy,
neurological disorders,
neuroscience,
patient care,
Phase 3 trial,
rare diseases,
refractory epilepsy,
sleep disorders,
treatment outcomes,
tuberous sclerosis complex,
Xywav
Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases
03/25/2026 | Companies
adenomyosis,
AI drug discovery,
artificial intelligence in healthcare,
ASKA Pharmaceutical,
biotechnology,
clinical-stage research,
disease target identification,
drug development,
endometriosis,
generative AI,
gynecological diseases,
Insilico Medicine,
medical innovation,
PandaOmics,
pharmaceutical collaboration,
reproductive health,
TargetPro,
therapeutic targets,
uterine fibroids,
women’s health
Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy
03/23/2026 | Companies
antibody therapeutics,
biologics,
biotech innovation,
chronic obstructive pulmonary disease,
clinical research,
COPD,
drug development,
half-life extension,
Harbour BioMed,
HBM9378,
immune-oncology,
immunological disorders,
immunology,
Kelun-Biotech,
monoclonal antibody,
pharmacokinetics,
Phase I clinical trial,
respiratory medicine,
safety profile,
severe asthma,
SKB378,
TSLP inhibitor,
WIN378
Belief BioMed & Grand Life Sciences Partner to Advance Hemophilia A Gene Therapy in China
03/23/2026 | Companies
BBM-H803,
BBM-H901,
Belief BioMed,
biotech industry,
biotechnology partnership,
China healthcare,
clinical development,
commercialization rights,
drug development,
gene therapy,
Grand Life Sciences,
healthcare innovation,
hematology,
hemophilia A,
hemophilia treatment,
innovative therapies,
medical research,
pharmaceutical collaboration,
rare diseases
Vimgreen Secures IND Approval for VG081821 in NASH Treatment
03/18/2026 | Companies
A2A receptor antagonist,
adenosine signalling,
biotechnology,
China CDE,
clinical trials,
drug development,
fibrosis,
hepatology,
IND approval,
inflammation,
inverse agonist,
lipophagy,
liver disease,
MASH,
metabolic disorders,
metabolic dysfunction associated steatohepatitis,
NASH,
non alcoholic steatohepatitis,
Parkinsons disease,
Phase II trial,
resmetirom,
semaglutide,
steatosis,
VG081821,
Vimgreen Pharmaceuticals
HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026
02/26/2026 | Companies
Syngene Extends Strategic Partnership with Bristol Myers Squibb Through 2035
01/21/2026 | Companies
biopharmaceutical industry,
Bristol Myers Squibb,
cardiovascular research,
clinical biomarkers,
clinical trials,
contract research organization,
CRDMO,
drug development,
drug discovery,
drug metabolism and pharmacokinetics,
end-to-end solutions,
fibrosis research,
global pharma,
immunology research,
innovation in healthcare,
integrated services,
life sciences,
manufacturing excellence,
oncology research,
patient-centric research,
pharmaceutical development,
pharmaceutical manufacturing,
preclinical development,
R&D partnership,
research collaboration,
strategic partnership,
Syngene International,
translational sciences
Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO
01/09/2026 | Companies
biopharmaceutical industry,
biotechnology innovation,
capital markets,
Chinese biotech,
clinical trials,
cornerstone investors,
drug development,
global offering,
healthcare innovation,
HKEX IPO,
Hong Kong Stock Exchange,
investor confidence,
liver-targeted delivery,
research and development,
Ribo Life Science,
RiboGalSTAR,
RNA interference,
siRNA therapeutics
Gilead Sciences Leads in Innovation & Responsibility
03/20/2025 | Companies
biopharmaceuticals,
corporate responsibility,
drug development,
employee empowerment,
Foster City California,
Gilead Sciences,
global health,
global operations,
healthcare,
innovative medicines,
life-threatening illnesses,
medical innovation,
medical research,
responsible business,
top biopharma companies
Enhancing Diversity in Clinical Trials: Why It Matters for Drug Development
01/15/2025 | Companies
clinical research,
clinical trial barriers,
clinical trial diversity,
clinical trial inclusion,
clinical trial participation,
clinical trial statistics,
clinical trials,
cultural competency,
diversity in clinical trials,
drug development,
ethnic diversity,
FDA guidelines,
health equity,
healthcare access,
healthcare disparities,
healthcare diversity,
medical research,
patient-centered development,
pharmaceutical industry,
Teva,
underrepresented groups
Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement
01/01/2025 | Companies
biotechnology,
Brii Biosciences,
BRII-179,
clinical trials,
combination therapies,
drug development,
elebsiran,
ENRICH study,
functional cure,
HBV,
healthcare innovation,
Hepatitis B Virus,
intellectual property acquisition,
know-how,
patents,
PEG-IFNα,
Phase 2b study,
shareholder value,
unmet medical needs,
VBI Vaccines
Companies
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com